Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects.

For EMBP, a downregulation in plasma was observed for both inhibitors (Figure 2 ) but was nominally significant for reslizumab ( p value = 7.16E‐05).

also in 7,732 other papers